[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sepsis-severe\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sepsis-severe":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,38,62,88,122,153,183,215,238,265,286,322],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":37},"100304523","bispectral-index-bis-for-classification-of-procalcitonin-pct-sepsis-grades-in-critically-ill-patients-with-sepsis-100304523",false,"NCT03244293","Bispectral Index (BIS) for Classification of Procalcitonin (PCT) Sepsis Grades in Critically Ill Patients With Sepsis","Sensitivity and Specificity of Bispectral Index (BIS) for Classification of Procalcitonin (PCT) Sepsis Grades in Critically Ill Patients With Sepsis, Severe Sepsis and Septic Shock and Multiple Organ Failure (MOF)","BIS6","Inclusion Criteria: patients with sepsis\n\n* patients with sepsis\n\nExclusion Criteria:\n\n* Patients who received drugs that would interfere with BIS monitoring","ALL",{"count":19,"type":20},20,"ESTIMATED","OBSERVATIONAL","To evaluate the discriminative power of BIS monitoring to classify the degree of mental state associated with the PCT graded sepsis cascade, and to assess its utility for monitoring the improvement or deterioration of sepsis.",[24],"Sepsis, Severe","RECRUITING","2026-04-22",{"date":28,"type":29},"2026-04-23","ACTUAL",{"date":31,"type":29},"2014-01-01",{"date":33,"type":20},"2030-12-01",{"name":35,"class":36},"Suez Canal University","OTHER",1,{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":42,"acronym":4,"eligibilityCriteria":43,"healthyVolunteers":11,"sex":17,"minAge":44,"maxAge":4,"enrollmentInfo":45,"targetDuration":47,"studyType":21,"phases":4,"briefSummary":48,"conditions":49,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":37},"100378163","sepsis-from-syndrome-to-personalized-care-100378163","NCT04203979","Sepsis: From Syndrome to Personalized Care","Inclusion Criteria:\n\n* admitted to emergency department OUH, Ullevål.\n* managed by the medical rapid response team or the sepsis rapid response team\n\nExclusion Criteria:\n\n* Not given informed consent by patient or next of kin (if patient is not able to)","18 Years",{"count":46,"type":20},1950,"1 Year","This is a prospective, observational study designed to examine the performance of biomarkers, molecular biological methods and other analysis in blood from patient with suspected sepsis in the Emergency department, as well as identidying novel sepsis endotypes. Around 1500 patients will be enrolled.",[50,51,24,52],"Sepsis Syndrome","Sepsis","Septic Shock","2026-03-17",{"date":55,"type":29},"2026-03-19",{"date":57,"type":29},"2020-01-06",{"date":59,"type":20},"2027-09-30",{"name":61,"class":36},"Oslo University Hospital",{"id":63,"slug":64,"hasResults":11,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":4,"eligibilityCriteria":68,"healthyVolunteers":11,"sex":17,"minAge":69,"maxAge":44,"enrollmentInfo":70,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":72,"conditions":73,"keywords":75,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":87},"100427780","treatment-strategy-of-human-gamma-globulin-on-the-therapy-for-intensively-ill-children-with-inflammatory-storm-100427780","NCT04850456","Treatment Strategy of Human Gamma Globulin on the Therapy for Intensively Ill Children With Inflammatory Storm","Treatment Strategy of Human Gamma Globulin in Children With Severe Infection Complicated With Inflammatory Storm : A Cohort Study","Inclusion Criteria:\n\n* children hospitalized in PICU of Children's Hospital of Fudan University\n* Children With Severe Infection Complicated With Inflammatory Storm\n\nExclusion Criteria:\n\n* discharge within 48 hours\n* patients without informed consent\n* incomplete clinical and demographic data","29 Days",{"count":71,"type":20},200,"The inflammatory storm in critically ill patients releases cytokines, causing systemic immune damage, which may be an important cause of multiple organ failure and even death. Inflammatory storms exacerbate the deterioration of the disease in those children. Gamma globulin may be an effective option to control inflammatory storms. However, this preliminary result needs to be verified from reliable and representative RCTs. In our study, we conducted a retrospective study on the use of gamma globulin and an unused control group. At present, the indications of IVIG are mainly focused on the neuromuscular system and the blood system. We hope to establish a more appropriate and operable evaluation table for the suitability of gamma globulin for clinical use.",[74,24],"Critical Illness",[51,74,76,77],"Inflammatory Storm","Gamma Globulin","2026-03-13",{"date":80,"type":29},"2026-03-16",{"date":82,"type":29},"2024-10-01",{"date":84,"type":20},"2026-12-31",{"name":86,"class":36},"Children's Hospital of Fudan University",2,{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":95,"sex":17,"minAge":44,"maxAge":4,"enrollmentInfo":96,"targetDuration":98,"studyType":21,"phases":4,"briefSummary":99,"conditions":100,"keywords":107,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":37},"100578328","role-of-transposable-elements-in-septic-immune-aging-100578328","NCT06809868","Role of Transposable Elements in Septic Immune Aging","SITE","Inclusion Criteria:\n\n* Age 18 or older\n* Admitted to ICU with sepsis (Sepsis 3 Criteria)\n* SOFA score of at least 2 at time of enrollment\n\nExclusion Criteria:\n\n* Patients on organ transplantation immunosuppression\n* Patients with preexisting leukopenia\n* Cancer patients receiving CAR-T therapy\n* Patients who are under 18 years of age or otherwise deemed pediatric\n* Patients with an ongoing bleeding diathesis (ie: DIC, hemorrhagic shock)\n* Patients with a chronic hemoglobin below 7.0\n* Patients who, prior to their ICU admission, are blood transfusion dependent",true,{"count":97,"type":20},116,"6 Weeks","The goal of this observational study is to learn about how transposable element levels affect the patient outcomes in sepsis. The main questions it aims to answer is:\n\n1. Do transposable elements prematurely age the immune systems of patients with sepsis?\n2. Do transposable elements correlate with increased mortality in patients with sepsis in the ICU?\n3. Do transposable elements correlate with increased amount of secondary infections in patients with sepsis in the ICU?\n\nParticipants will have blood drawn from them but will not be subjected to additional interventions.",[51,101,102,103,24,104,105,106],"Sepsis and Septic Shock","Sepsis With Multiple Organ Dysfunction (MOD)","Sepsis With Acute Organ Dysfunction","Sepsis at Intensive Care Unit","Sepsis, Severe Sepsis and Septic Shock","Sepsis, Septic Shock",[51,108,109,110,111,112],"Transposable Elements","Immune Aging","Mortality","Secondary Infections","Critical Care Medicine (ICU)","2026-01-28",{"date":115,"type":29},"2026-01-30",{"date":117,"type":29},"2025-02-14",{"date":119,"type":20},"2028-08-14",{"name":121,"class":36},"University of California, San Francisco",{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":128,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":17,"minAge":44,"maxAge":4,"enrollmentInfo":130,"targetDuration":4,"studyType":132,"phases":133,"briefSummary":135,"conditions":136,"keywords":139,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":37},"100532832","early-intravenous-hydrocortisone-in-sepsis-100532832","NCT06217939","Early Intravenous Hydrocortisone in Sepsis","Early Intravenous Hydrocortisone in Sepsis: a Randomized Control Trial","EARL-HYDRO","Inclusion Criteria:\n\n* Age of 18 years or older\n* Suspected or definite sepsis Sepsis is defined by SEPSIS-3 definition as Sequential Organ Failure Assessment (SOFA) score ≥ 2 from baseline with suspected infection.2 Suspected sepsis is defined as patients with suspected infection who meet 2 or more criteria of quick SOFA (altered mentation, respiratory rate ≥ 22\u002Fmin, systolic blood pressure ≤ 100 mmHg).\n* Hypotension (mean arterial pressure \\< 65 mmHg)\n\nExclusion Criteria:\n\n* Randomization and administration of the study drugs are not able to be executed within 3 hours after the onset of hypotension\n* Causes of shock other than sepsis identified\n* Immunocompromised A patient is considered immunocompromised if one of the following criteria is met: history of human immunodeficiency virus infection or acquired immunodeficiency syndrome, hematologic malignancy, receiving chemotherapy, active cancer receiving chemotherapy, current use of immunosuppressive medication)\n* Hyperglycemic crisis (diabetic ketoacidosis, hyperosmolar hyperglycemic state)\n* Pregnancy\n* Post-cardiac arrest\n* Received etomidate before randomization\n* Systemic corticosteroids indicated for other conditions\n* Received systemic corticosteroids within 4 weeks at any dose\n* Cancer patients who are receiving palliative treatment\n* Do-not-resuscitate order",{"count":131,"type":20},230,"INTERVENTIONAL",[134],"NA","The goal of this clinical trial is to compare two timings of steroid treatment in patients with severe infection who develop low blood pressure.\n\nThe main question it aims to answer is:\n\n• Which timing strategy is better between starting steroid treatment very early in the course of severe infection, or waiting until the patient does not respond to medicine that raises blood pressure according to the current guidelines?\n\nParticipants will receive either early steroid treatment or placebo right after they develop low blood pressure from infection. Both participants and treating doctors will not know which treatment participants received. When blood pressure goal is not reached after a moderate dose of drugs that raise blood pressure, an open-label steroid treatment will be given to participants as indicated in the current guidelines.",[137,138],"Sepsis Severe","Shock, Septic",[140,141,142,143],"sepsis","hydrocortisone","shock","early","2026-01-05",{"date":146,"type":29},"2026-01-07",{"date":148,"type":29},"2024-06-25",{"date":150,"type":20},"2026-09",{"name":152,"class":36},"Siriraj Hospital",{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":157,"acronym":158,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":17,"minAge":44,"maxAge":4,"enrollmentInfo":160,"targetDuration":47,"studyType":21,"phases":4,"briefSummary":162,"conditions":163,"keywords":168,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":182},"100529826","towards-novel-biomarkers-to-diagnose-sepsis-on-the-emergency-room-100529826","NCT06178822","Towards Novel BIOmarkers to Diagnose SEPsis on the Emergency Room","BIOSEP","Inclusion Criteria:\n\n* Age 18 years or higher\n* Presentation at the Emergency Department (ED)\n* Clinical suspicion of infection or earlier confirmed infection\n* Modified Early Warning Score (MEWS) of 2 or higher\n\nExclusion Criteria:\n\n* No informed consent given",{"count":161,"type":20},3300,"Objectives:\n\n1. To compare the immune response of patients with or without sepsis presenting to the ED with a(n) (suspected) infection.\n2. To determine immune response aberrations that are associated with an increased risk of developing sepsis in patients presenting to the ED with a(n) (suspected) infection without sepsis.\n3. To determine the long term cognitive and physical sequelae of sepsis after admission.",[51,52,24,164,165,166,167],"Infections","Infection Viral","Infection, Bacterial","Infections, Respiratory",[169,170,171,172],"Biomarkers","Emergency Room","A&E","Accident & Emergency","2025-09-29",{"date":175,"type":29},"2025-10-02",{"date":177,"type":29},"2022-10-25",{"date":179,"type":20},"2026-10-01",{"name":181,"class":36},"Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC)",3,{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":189,"eligibilityCriteria":190,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":191,"targetDuration":4,"studyType":132,"phases":193,"briefSummary":194,"conditions":195,"keywords":200,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":214},"100514221","reducing-empiric-vancomycin-use-in-pediatric-suspected-sepsis-100514221","NCT05975671","Reducing Empiric VAncomycin Use in Pediatric Suspected Sepsis","Reducing Empiric VAncomycin Use in Pediatric Suspected Sepsis (REVAMP-Sepsis)","REVAMP","Patient Inclusion Criteria:\n\n* Admitted to one of the participating PICUs during the study period\n\nPatient Exclusion Criteria:\n\n* None\n\nClinician Inclusion Criteria:\n\n1. PICU prescribing clinician (including attending physicians, fellows, residents, nurse practitioners, and physician assistants) OR sepsis stakeholder (leader of sepsis quality improvement work, medical director) at one of the participating sites at the time the survey is deployed\n2. Age ≥ 18 years old\n3. Employed by one of the participating sites\n\nClinician Exclusion Criteria:\n\n1. Volunteers or other non-employee hospital staff\n2. Limited English proficiency",{"count":192,"type":20},52500,[134],"The goal of this quasi-experimental interventional study is to determine the effectiveness of a multifaceted stewardship intervention in reducing overall vancomycin use in five tertiary care Pediatric Intensive Care Units (PICU).\n\nThere are two groups of subjects in this study: PICU clinicians\u002Fsepsis stakeholders and patients admitted to one of the participating PICUs during the study period. The intervention will at a minimum include:\n\n* Implementation of a clinical guideline indicating when vancomycin should and should not be used\n* Unit-level feedback on overall vancomycin use within and across centers\n* Clinician education.",[51,196,197,198,24,52,199],"Sepsis Mrsa","Sepsis Bacteremia","Antimicrobial - Induced Nephropathy","Septic Syndrome",[51,201,202,203,204],"Vancomycin use","methicillin-resistant Staphylococcus aureus (MRSA)","Antibiotic Stewardship","Implementation science","2025-09-17",{"date":207,"type":29},"2025-09-19",{"date":209,"type":29},"2023-08-21",{"date":211,"type":20},"2026-05",{"name":213,"class":36},"Children's Hospital of Philadelphia",4,{"id":216,"slug":217,"hasResults":11,"nctId":218,"briefTitle":219,"officialTitle":219,"acronym":220,"eligibilityCriteria":221,"healthyVolunteers":11,"sex":17,"minAge":44,"maxAge":4,"enrollmentInfo":222,"targetDuration":4,"studyType":132,"phases":224,"briefSummary":226,"conditions":227,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":19},"100473270","phase-2-recovery-from-acute-immune-failure-in-septic-shock-by-immune-cell-extracorporeal-therapy-100473270","NCT05442710","Recovery From Acute Immune Failure in Septic Shock by Immune Cell Extracorporeal Therapy","ReActiF-ICE","Inclusion Criteria:\n\n1. Adult subjects\n\n   1. ≥ 18 years of age\n   2. with septic shock, defined as those with septic shock according to\" Sepsis-3-Definition\" who additionally require norepinephrine at a dose of ≥ 0.15 mcg\u002Fkg\u002Fmin (and\u002For vasopressin at any dose) for a minimum of 6 hours (within the last 48 hours), to maintain a MAP ≥65 mmHg\n   3. Subjects ≥ 80 years of age shall have a Clinical Frailty Scale of \\\u003C5 to be enrolled.\n2. Fulfillment of the definition of septic shock, not longer than 48h before randomization. I.e. the 48h start at the end of the 6h period.\n3. Blood lactate \\>2 mmol\u002FL despite adequate volume resuscitation during the current sepsis episode\n4. Source control achieved \u002F in progress in the judgement of the investigator\n5. Subjects are required to have central venous access and an arterial line, and these are expected to remain present for at least the initial 48 hours of study.\n6. Subjects must have received adequate volume replacement in the judgement of the investigator.\n7. Subject or legal surrogate is willing and able to provide written informed consent and comply with all protocol requirements or confirmation of the urgency of participation in the clinical trial and the possible benefit to the subject by an independent consultant or the implementation of other established procedures according to the local regulations of the contributing centre to include subjects who are unable to provide informed consent.\n\nExclusion Criteria:\n\n1. Acute or chronic leukemia,\n2. Bilirubin ≥ 2 mg\u002FdL (≥33 µmol\u002FL),\n3. Ongoing (concomitant) or prior within the last 6 month any chemotherapy or radiotherapy for malignancy,\n4. Autoimmune disease with systemic medication of ≥10 mg prednisolone equivalent,\n5. Previous transplantation,\n6. Subjects receiving interferon therapy (14 days prior randomisation),\n7. Acute pulmonary embolism within the last 72 hours,\n8. Ischemic stroke or intracranial bleeding within the last 3 months\n9. Suspicion of concomitant acute coronary syndrome based on clinical symptoms and\u002For ECG within the last 72 hours,\n10. Cardiopulmonary resuscitation within last 7 days,\n11. Moribund subject (life expectancy \\\u003C72 hours), in the judgement of the investigator\n12. Presence of a do-not-resuscitate or do-not-intubate order,\n13. Known HIV infection or chronic viral hepatitis,\n14. Isolated Urosepsis,\n15. Pregnancy\u002Fnursing period,\n16. Primary cause of hypotension not due to sepsis (e.g. major trauma including traumatic brain injury, haemorrhage, burns, or congestive heart failure\u002Fcardiogenic shock),\n17. Previous sepsis with ICU admission within this hospital stay,\n18. Known\u002Fsuspected acute mesenteric ischaemia,\n19. Chronic mechanical ventilation for any reason OR severe COPD requiring either continuous daily oxygen use during the preceding 30 days or mechanical ventilation (for acute exacerbation of COPD) during the preceding 30 days,\n20. Decision to limit full care taken before obtaining informed consent,\n21. Prior enrolment in the trial,\n22. Prior use of an investigational medicinal product within the last month OR planned or concurrent participation in a clinical trial for any investigational drug or device,\n23. multiple injuries including polytrauma and burn \\>20% TBSA (2° or 3°),\n24. Diagnosed and documented pre-existing dementia,\n25. Severe Covid-Pneumonia",{"count":223,"type":20},142,[225],"PHASE2","Evaluation of a novel therapy approach for severe sepsis patients. Subjects randomized into the treatment arm receive treatment with an immune cell perfusion system on top of standard care.\n\nThis may contribute to the improvement of the impaired organ function of septic shock patients by assisting the impaired immune system (immune competence enhancement = ARTICE)",[24],"2025-05-21",{"date":230,"type":29},"2025-05-25",{"date":232,"type":29},"2022-07-24",{"date":234,"type":20},"2026-06-30",{"name":236,"class":237},"Artcline GmbH","INDUSTRY",{"id":239,"slug":240,"hasResults":11,"nctId":241,"briefTitle":242,"officialTitle":243,"acronym":244,"eligibilityCriteria":245,"healthyVolunteers":11,"sex":17,"minAge":44,"maxAge":4,"enrollmentInfo":246,"targetDuration":4,"studyType":132,"phases":247,"briefSummary":249,"conditions":250,"keywords":251,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":37},"100503516","phase-4-early-administration-of-norepinephrine-in-sepsis-100503516","NCT05836272","Early Administration of Norepinephrine in Sepsis","Early Administration of Norepinephrine in Sepsis (Tunisian Multicenter Randomized Trial)","EA-NE-TUN","Inclusion Criteria:\n\n* Age 18 or older.\n* The patient or his\u002Fher legal representative has given informed consent in writing.\n* Diagnosis of sepsis according to the definitions updated by the consensus of sepsis 3.\n* Mean arterial pressure \\\u003C 65 mmHg\n\nExclusion Criteria:\n\n* Diagnosis of septic shock prior to randomization (where NA requirements exceed those of the trial protocol)\n* Pregnancy,\n* Need for immediate surgery,\n* Neoplasia at an advanced stage\n* Circumstances where water restriction is the rule:\n* Acute pulmonary edema\n* Acute coronary syndrome,",{"count":71,"type":20},[248],"PHASE4","The management of septic states includes, in addition to the specific treatment (antimicrobials and eradication of the source), a restoration of the hemodynamic disorders and assistance of the failing organs. In general, the restoration of hemodynamic disorders begins first with volume expansion, followed by the use of Noepinephrine (NE) when the target mean arterial pressure (MAP) is not reached after optimizing the intravascular volume. Recently, several studies have supported the interest of early NE on MAP, cardiac output and mortality. It is therefore tempting to restrict fluid administration even in the initial phase of hemodynamic management of severe sepsis by starting NE earlier.",[24],[140,252,253,254,255],"septic shock","Norepinephrine","volume expansion","mortality","2024-12-02",{"date":258,"type":29},"2024-12-04",{"date":260,"type":29},"2023-08-01",{"date":262,"type":20},"2025-08",{"name":264,"class":36},"Tunis University",{"id":266,"slug":267,"hasResults":11,"nctId":268,"briefTitle":269,"officialTitle":270,"acronym":4,"eligibilityCriteria":271,"healthyVolunteers":11,"sex":17,"minAge":44,"maxAge":272,"enrollmentInfo":273,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":275,"conditions":276,"keywords":4,"overallStatus":277,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":282,"leadSponsor":284,"locationsCount":4},"100561190","accuracy-of-venous-excess-ultrasound-vexus-score-versus-central-venous-pressure-in-patients-with-severe-sepsis-100561190","NCT06586931","Accuracy of Venous Excess Ultrasound (VEXUS) Score Versus Central Venous Pressure in Patients With Severe Sepsis","Accuracy of Venous Excess Ultrasound (VEXUS) Score Versus Central Venous Pressure to Assess Volume Status in Patients With Severe Sepsis","Inclusion Criteria:\n\n* adult patients (≥ 18 years old) with the diagnosis of severe sepsis and clinical indication to be admitted in critical care units are recruited. Sepsis should be suspected to be the primary cause of their acute illness by the treating physician, consistent with the\n\nSurviving Sepsis Campaign Guidelines (2021) :\n\n* Life-threatening organ dysfunction\n* Diagnosis of infection Some patients diagnosed with sepsis will not meet the criteria, but will be eligible for the study if the treating physician makes a clinical diagnosis of severe sepsis.\n\nExclusion Criteria:\n\n* 1\\. Refusal to participate 2. Patients in hemodialysis program 3. Patients with previously known conditions that interfere with portal Doppler assessments, namely liver cirrhosis, or severe tricuspid regurgitation with structural heart disease. If any of these conditions are identified during the present episode, the patient would also be excluded.\n\n  4\\. Age \\\u003C 18 years 5. Patients subjected to withdrawal of care 6. Hemodynamic instability due to active hemorrhage 7. Acute coronary syndrome 8. Indication for immediate surgery 9. Received CPR within 24 hours of enrollment 10. Pregnancy","75 Years",{"count":274,"type":20},60,"assessing septic patients with a noninvasive ultrasound protocol, and earlier identification of fluid overload to help clinicians decide whether to administer supplemental fluid therapy or suspend its administration and to evaluate the possible relation between the different VExUS grades and the adverse effects of intensive fluid administration",[24],"NOT_YET_RECRUITING","2024-09-04",{"date":280,"type":29},"2024-09-19",{"date":82,"type":20},{"date":283,"type":20},"2025-11",{"name":285,"class":36},"Minia University",{"id":287,"slug":288,"hasResults":11,"nctId":289,"briefTitle":290,"officialTitle":291,"acronym":292,"eligibilityCriteria":293,"healthyVolunteers":95,"sex":17,"minAge":44,"maxAge":294,"enrollmentInfo":295,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":297,"conditions":298,"keywords":306,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":314,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":320,"locationsCount":37},"100289166","monocyte-profiles-in-critically-ill-patients-with-pseudomonas-aeruginosa-sepsis-100289166","NCT03044223","Monocyte Profiles in Critically Ill Patients With Pseudomonas Aeruginosa Sepsis","Phenotypical Und Functional Characterization of Macrophages in Critically Ill Patients With Pseudomonas Aeruginosa Induced Sepsis","MIPSA","Inclusion Criteria:\n\n* age \\> 18 years\n* critically ill patients with sepsis\n* microbiologically proven infection with Pseudomonas aeruginosa\n\nExclusion Criteria:\n\n* life expectancy \\\u003C 24 hours\n* participation in other studies","90 Years",{"count":296,"type":20},100,"The present study focuses on patients with Pseudomonas aeruginosa (PSA) sepsis. The aim of the present study is to find out whether the M1 (pro-inflammatory) or M2 (anti-inflammatory) phenotype predominates in blood monocytes in critically ill patients with PSA-sepsis, and whether the severity of sepsis and outcome is associated with distinct monocyte phenotype and function.",[299,300,301,302,303,304,51,24,305],"Pseudomonas Infections","Pseudomonas Septicemia","Pseudomonas; Pneumonia","Pseudomonal Bacteraemia","Pseudomonas Urinary Tract Infection","Pseudomonas Gastrointestinal Tract Infection","Critically Ill",[307,308,140,309,310,311,312],"pseudomonas aeruginosa","critically ill patient","monocyte","macrophage","cytokine","severity of disease","2024-01-16",{"date":315,"type":29},"2024-01-17",{"date":317,"type":4},"2014-08",{"date":319,"type":20},"2026-12",{"name":321,"class":36},"University of Ulm",{"id":323,"slug":324,"hasResults":11,"nctId":325,"briefTitle":326,"officialTitle":326,"acronym":327,"eligibilityCriteria":328,"healthyVolunteers":11,"sex":17,"minAge":44,"maxAge":4,"enrollmentInfo":329,"targetDuration":4,"studyType":132,"phases":331,"briefSummary":332,"conditions":333,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":335,"startDateStruct":337,"completionDateStruct":339,"leadSponsor":341,"locationsCount":37},"100477052","assessment-for-implementation-methods-in-sepsis-100477052","NCT05491941","Assessment for Implementation Methods in Sepsis","AIMS","Inclusion Criteria:\n\n* Adults \\>=18\n* Patient meets criteria for time zero (sepsis within 6 hours of ED triage and the 3 criteria-infection, 2 SIRS and 1 or more organ dysfunctions, must be met within 3 hours of each other.\n\nExclusion Criteria:\n\n* Last admission for patients admitted to same hospital once\n* Pregnant women\n* All transfers from another hospital\n* Individuals who are made comfort care only within 6 hours of admission to ED\n* Moribund patients",{"count":330,"type":20},10000,[134],"Since the introduction of sepsis bundles, there have been multiple published trials that have demonstrated a consistent, strong association between implementation of sepsis \"bundles\" (3-hour bundle) and improved survival. The current proposal is a Hybrid 2, pragmatic, cluster randomized clinical effectiveness\u002Fimplementation trial evaluating mortality and respiratory failure-based outcomes, in patients admitted to the emergency department with sepsis, comparing the effectiveness of implementation of the hour-1 bundle to 3-hour bundle, while facilitating adherence to both bundles. In addition, 4 distinct sepsis phenotypes will be derived from routine clinical data to identify specific patient phenotypes that allow for a more precision-based application of sepsis bundles in future studies.",[137,52],"2022-08-04",{"date":336,"type":29},"2022-08-08",{"date":338,"type":29},"2022-07-15",{"date":340,"type":20},"2027-07-15",{"name":342,"class":36},"Rhode Island Hospital"]